Five to 10% of the adult population will develop a clinically apparently thyroid nodule in their lifetime. Only a small proportion of these individuals, however, will turn out to harbor a malignant neoplasm. Differential diagnosis of thyroid nodules is often problematic prior to surgical resection, and even after careful histological examination of the resected tissue the nature of some follicular neoplasms remains unclear. The experiments outlined in this proposed aim to identify molecular factors associated with abnormal thyroid cell growth, in an attempt to increase our understanding of the biology of these tumors. In the first portion of these studies, we will determine the clonal characteristics of the various types of thyroid adenomas and carcinomas. This will be done by X-chromosome in activation analysis, taking advantage of polymorphisms in the X-chromosome genes hypoxanthine phosphorybosiltransferase (HPRT) and phosphoglycerate kinase (PGK). Evidence pointing to a monoclonal origin of these tumors will provide support for a somatic mutation model of thyroid neoplastic formation. Clonal studies will also be performed on multiple nodules obtained from patient with multinodular goiters, to assess the frequency of monoclonal neoplasms following exposure to goitrogenic stimuli in these patients. In the second part of the proposal we will examine thyroid tumor DNA for structural mutations of proto-oncogene sequences. These experiments have been prompted by our preliminary data showing H-ras gene rearrangements in some thyroid neoplasms. Polymerase chain reaction DNA amplification of thyroid tumor DNA will also be performed to screen for the presence of ras gene point mutations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA050706-03
Application #
3459612
Study Section
Pathology B Study Section (PTHB)
Project Start
1989-08-01
Project End
1994-07-31
Budget Start
1991-08-01
Budget End
1992-07-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Landa, IƱigo; Ibrahimpasic, Tihana; Boucai, Laura et al. (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-66
Garcia-Rendueles, Maria E R; Ricarte-Filho, Julio C; Untch, Brian R et al. (2015) NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov 5:1178-93
Dunn, Lara; Fagin, James A (2015) Therapy: Lenvatinib and radioiodine-refractory thyroid cancers. Nat Rev Endocrinol 11:325-7
Ricarte-Filho, Julio C; Li, Sheng; Garcia-Rendueles, Maria E R et al. (2013) Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest 123:4935-44
Montero-Conde, Cristina; Ruiz-Llorente, Sergio; Dominguez, Jose M et al. (2013) Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3:520-33
Ricarte-Filho, Julio C; Matsuse, Michiko; Lau, Christopher et al. (2012) Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. Int J Cancer 130:2215-7; author reply 2217-8
Chakravarty, Debyani; Santos, Elmer; Ryder, Mabel et al. (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121:4700-11
Knauf, J A; Sartor, M A; Medvedovic, M et al. (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF? signaling. Oncogene 30:3153-62
Franco, Aime T; Malaguarnera, Roberta; Refetoff, Samuel et al. (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A 108:1615-20
Fagin, James A; Tuttle, R Michael; Pfister, David G (2010) Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab 95:2621-4

Showing the most recent 10 out of 12 publications